Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Nausea, Vomiting
Ginger Control of Chemotherapy Induced Nausea and Vomiting
This is a trial to determine the safety and efficacy of ginger in reducing the prevalence and severity of chemotherapy induced nausea and vomiting.
- Conditions
- Nausea, Vomiting, Chemotherapy
- Trial name
- NCT00065221
- Testing
- Ginger
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Breast Neoplasms, Nausea
Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients
To evaluate the feasibility of a three-parallel-arm, placebo-controlled randomized trial using a standard auricular acupressure protocol for managing nausea and vomiting in a homogenous group of female breast cancer patients…
- Conditions
- Breast Neoplasms, Nausea, Vomiting
- Trial name
- NCT02403037
- Testing
- True auricular acupressure, Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
- Where
- 3 sites in China
- Volunteers
- 114 people
- Sponsor
- The Hong Kong Polytechnic University
Carcinoma, Non-small Cell Lung
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control…
- Trial name
- NCT02161991
- Testing
- Aprepitant
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Hunan Province Tumor Hospital
Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting
Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults…
- Trial name
- NCT07768124
- Testing
- 5-HT3 receptor antagonist (e.g., ondansetron), Acupoint application
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiu Huang
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting
A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
- Trial name
- NCT00990821
- Testing
- 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)
This is a multicenter, randomized, open-label, paralleled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) efficacy compared with the ondansetron…
- Trial name
- NCT01659775
- Testing
- Sancuso patch, Zofran inj.+Zofran tab.
- Where
- South Korea
- Volunteers
- 389 people
- Sponsor
- LG Life Sciences
Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting
Nausea and vomiting are common problems for cancer patients. Half of them will experience these symptoms during the course of their disease, either because of the cancer itself or because of their treatment1.
- Trial name
- NCT01581918
- Testing
- Carbamazepine
- Where
- Brazil
- Volunteers
- 43 people
- Sponsor
- Faculdade de Medicina do ABC
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Chemotherapy-induced Nausea and Vomiting
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in…
- Trial name
- NCT03601871
- Testing
- Thalidomide, Dexamethasone, 5-HT3 antagonists
- Where
- 29 sites in China
- Volunteers
- 880 people
- Sponsor
- Yunpeng Liu
Chemotherapy-induced Nausea and Vomiting
Acupuncture for Chemotherapy-Induced Nausea and Vomiting
The purpose of this study is to clarify whether the matching acupoints is more effective than a single point by electroacupuncture in the management of chemotherapy-induced nausea and vomiting .
- Trial name
- NCT02195921
- Testing
- single point Zhongwan(CV12) plus antiemetic drug, single point Zusanli(ST36) plus antiemetic drug, Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tianjin University of Traditional Chinese Medicine
Reflexology
Complementary Effect of Reflexology on Chemotherapy-Induced Nausea and Vomiting
Reflexology treatment may influence the severity of chemotherapy-induced nausea and vomiting. This study aims to investigate the clinical effect of reflexology on chemotherapy-induced nausea and vomiting.
- Trial name
- NCT02653820
- Testing
- Reflexology
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Hillel Yaffe Medical Center
Chemotherapy-induced Nausea and Vomiting
Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
- Trial name
- NCT05319860
- Testing
- Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Nausea and Vomiting
The Effect of Acupuncture in Chemotherapy-induced Nausea and Vomiting
Nausea and vomiting are the most common symptoms experienced by cancer patients after chemotherapy. Some patients have to endure such unpleasant symptoms even after using of antiemetic or anti-vomiting medications.The purpose of…
- Trial name
- NCT02369107
- Testing
- Verum acupuncture and medicine
- Volunteers
- 136 people
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
Ovarian Cancer, Uterine Cancer
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies.
- Trial name
- NCT01432015
- Testing
- fosaprepitant, aprepitant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gynecologic Oncology Associates
Acute Leukemia
Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy
Chemotherapy induced nausea is a common side effect for children undergoing chemotherapy. Furthermore, chemotherapy-induced vomiting is a major factor limiting quality of life during treatment reported by paediatric cancer…
- Trial name
- NCT01661413
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- The Hospital for Sick Children
Neoplasms, Nausea
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron 0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and vomiting induced by moderately emetogenic…
- Conditions
- Neoplasms, Nausea, Vomiting
- Trial name
- NCT00687011
- Testing
- Palonosetron and Dexamethasone
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC